Jubilant Ingrevia Limited has successfully concluded its postal ballot voting process, with shareholders approving the reappointment of Mrs. Ameeta Chatterjee as an Independent Director for a second term of five years. The company announced the voting results on April 06, 2026, following the completion of the remote e-voting process conducted under Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Voting Results and Participation

The special resolution for Mrs. Ameeta Chatterjee's reappointment (DIN: 03010772) received overwhelming shareholder support with 97.95% approval. The voting process attracted significant participation from the company's shareholder base across all categories.

Category-wise Voting Breakdown

The voting results demonstrated strong support across all shareholder categories. Promoter and promoter group shareholders showed unanimous support, while public shareholders also endorsed the resolution with substantial majorities.

Voting Process and Timeline

The postal ballot process was conducted entirely through remote e-voting in compliance with regulatory requirements. The company issued the postal ballot notice on February 04, 2026, with February 26, 2026, serving as the cut-off date for determining eligible shareholders.

Regulatory Compliance and Documentation

CS Rupinder Singh Bhatia served as the scrutinizer for the voting process, ensuring transparency and compliance with statutory requirements. The scrutinizer's report dated April 06, 2026, confirmed that the resolution was passed with requisite majority. The company published advertisements in Financial Express (English edition) and Dainik Jagran-Moradabad (Hindi edition) on March 6, 2026, informing shareholders about the postal ballot notice.

The remote e-voting facility was provided through the National Securities Depository Limited platform at eservices.nsdl.com. Company Secretary Deepanjali Gulati digitally signed the official communication to BSE Limited and National Stock Exchange of India Limited, confirming the successful completion of the postal ballot process.

Resolution Details

The approved special resolution pertains to the reappointment of Mrs. Ameeta Chatterjee as an Independent Director for a second consecutive term of five years. The promoter and promoter group were not interested in this particular resolution, ensuring independent shareholder decision-making on the matter. The resolution was declared passed with effect from April 4, 2026, being the last date of remote e-voting for the company's members.

Jubilant Ingrevia Limited has successfully completed its acquisition of 100% equity stake in Remidex Pharma Private Limited, marking a significant milestone in the company's strategic expansion within the pharmaceutical sector. The transaction was completed on March 30, 2026 at 6:05 pm IST, following the Share Purchase Agreement that was initially announced on March 13, 2026.

Transaction Completion Details

The acquisition represents the culmination of a strategic process that began with the Share Purchase Agreement entered into between Jubilant Ingrevia and Remidex Pharma Private Limited. The company has fulfilled all regulatory disclosure requirements under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance and Disclosure

Jubilant Ingrevia has maintained full compliance with regulatory requirements throughout the acquisition process. The company initially disclosed the transaction details on March 13, 2026, providing all necessary information pursuant to Regulation 30 read with SEBI Master Circular No: HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026.

The completion of this acquisition has been formally communicated to both BSE Limited and National Stock Exchange of India Limited, ensuring full transparency with all stakeholders. The company has also updated its website with relevant documentation related to this transaction.

Strategic Implications

This acquisition strengthens Jubilant Ingrevia's position in the pharmaceutical sector by bringing Remidex Pharma's capabilities and assets under its direct control. The 100% equity acquisition provides the company with complete operational control over Remidex Pharma's business operations and strategic direction.

The successful completion of this transaction demonstrates Jubilant Ingrevia's commitment to growth through strategic acquisitions and its ability to execute complex corporate transactions within established timelines. The acquisition aligns with the company's broader expansion strategy in the pharmaceutical and specialty chemicals sectors.